To resolve the controversial question raised by this evidence and provide more statistical power for detecting the significance of -160C/A to cancer risk, we performed a meta-analysis on the 160C/A polymorphism of E-cadherin and cancer risk with 47 case-control studies including 18,194 cases and 20,207 controls as of March 2012. The gene discussed is CDH1; the disease is cancer.